ELDN — Eledon Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $101.66m
- $58.80m
- 46
- 32
- 83
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.41 | ||
| Price to Tang. Book | 2.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -55.84% | ||
| Return on Equity | -53.27% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 50 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Directors
- Keith Katkin NEC (49)
- Steven Perrin PRE (56)
- David-Alexandre Gros CEO (49)
- Paul Little CFO (57)
- Bryan Smith CCO (41)
- Jeff Bornstein OTH
- David Hovland OTH
- Jan Hillson IND (66)
- June Lee IND (55)
- Gary Lyons IND (70)
- John McBride IND (68)
- Walter Ogier IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 26th, 2004
- Public Since
- September 17th, 2014
- No. of Shareholders
- 44
- No. of Employees
- 20
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 38,506,614
- Address
- 19800 MACARTHUR BLVD., SUITE 250, IRVINE, 92612
- Web
- https://eledon.com/
- Phone
- +1 9492388090
- Auditors
- KMJ Corbin & Company LLP
Upcoming Events for ELDN
Q2 2024 Eledon Pharmaceuticals Inc Earnings Release
Q3 2024 Eledon Pharmaceuticals Inc Earnings Release
Similar to ELDN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Eledon Pharmaceuticals share price?
As of Today at 20:28 UTC, shares in Eledon Pharmaceuticals are trading at $2.73. This share price information is delayed by 15 minutes.
How has the Eledon Pharmaceuticals share price performed this year?
Shares in Eledon Pharmaceuticals last closed at $2.73 and the price had moved by +78.43% over the past 365 days. In terms of relative price strength the Eledon Pharmaceuticals share price has outperformed the S&P500 Index by +41.98% over the past year.
What are the analyst and broker recommendations for Eledon Pharmaceuticals?
The overall consensus recommendation for Eledon Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Eledon Pharmaceuticals dividend yield?
Eledon Pharmaceuticals does not currently pay a dividend.
Does Eledon Pharmaceuticals pay a dividend?
Eledon Pharmaceuticals does not currently pay a dividend.
When does Eledon Pharmaceuticals next pay dividends?
Eledon Pharmaceuticals does not currently pay a dividend.
How do I buy Eledon Pharmaceuticals shares?
To buy shares in Eledon Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eledon Pharmaceuticals?
As of the previous close price of $2.73, shares in Eledon Pharmaceuticals had a market capitalisation of $105.12m.
Where are Eledon Pharmaceuticals shares listed?
Here are the trading details for Eledon Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ELDN
What kind of share is Eledon Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Eledon Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eledon Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Eledon Pharmaceuticals is $14.00. That is 412.82% above the last closing price of $2.73.
Analysts covering Eledon Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.15 for the next financial year.
What is the trend in the Eledon Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eledon Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +55.91%.
As of the last closing price of $2.73, shares in Eledon Pharmaceuticals were trading +53.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eledon Pharmaceuticals PE Ratio?
The Eledon Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eledon Pharmaceuticals?
Eledon Pharmaceuticals' management team is headed by:
- Keith Katkin - NEC
- Steven Perrin - PRE
- David-Alexandre Gros - CEO
- Paul Little - CFO
- Bryan Smith - CCO
- Jeff Bornstein - OTH
- David Hovland - OTH
- Jan Hillson - IND
- June Lee - IND
- Gary Lyons - IND
- John McBride - IND
- Walter Ogier - IND